Raymond James Financial Services Advisors’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $56.5M | Buy |
674,764
+63,071
| +10% | +$4.97M | 0.08% | 245 |
|
|
2024
Q2 | $47.1M | Buy |
611,693
+77,677
| +15% | +$5.69M | 0.07% | 271 |
|
|
2024
Q1 | $36.6M | Buy |
534,016
+26,466
| +5% | +$1.7M | 0.05% | 327 |
|
|
2023
Q4 | $29.3M | Buy |
507,550
+14,723
| +3% | +$786K | 0.05% | 370 |
|
|
2023
Q3 | $26M | Buy |
492,827
+113,832
| +30% | +$5.97M | 0.05% | 372 |
|
|
2023
Q2 | $20.5M | Buy |
378,995
+13,195
| +4% | +$689K | 0.04% | 463 |
|
|
2023
Q1 | $18.3M | Buy |
365,800
+67,007
| +22% | +$3.16M | 0.03% | 474 |
|
|
2022
Q4 | $13.8M | Buy |
298,793
+74,668
| +33% | +$3.23M | 0.03% | 542 |
|
|
2022
Q3 | $8.68M | Buy |
224,125
+11,881
| +6% | +$477K | 0.02% | 682 |
|
|
2022
Q2 | $7.91M | Buy |
212,244
+10,214
| +5% | +$416K | 0.02% | 725 |
|
|
2022
Q1 | $8.95M | Sell |
202,030
-29,365
| -13% | -$1.27M | 0.02% | 737 |
|
|
2021
Q4 | $9.83M | Sell |
231,395
-175,378
| -43% | -$7.37M | 0.02% | 692 |
|
|
2021
Q3 | $17.6M | Buy |
406,773
+4,963
| +1% | +$220K | 0.04% | 482 |
|
|
2021
Q2 | $17.2M | Buy |
401,810
+2,508
| +0.6% | +$106K | 0.04% | 486 |
|
|
2021
Q1 | $15.4M | Buy |
399,302
+26,088
| +7% | +$987K | 0.03% | 468 |
|
|
2020
Q4 | $13.4M | Buy |
373,214
+213,276
| +133% | +$7.69M | 0.03% | 467 |
|
|
2020
Q3 | $6.11M | Sell |
159,938
-10,267
| -6% | -$396K | 0.02% | 684 |
|
|
2020
Q2 | $5.98M | Buy |
170,205
+24,062
| +16% | +$867K | 0.02% | 639 |
|
|
2020
Q1 | $4.77M | Sell |
146,143
-46,295
| -24% | -$1.81M | 0.02% | 555 |
|
|
2019
Q4 | $8.7M | Buy |
192,438
+27,680
| +17% | +$1.16M | 0.03% | 546 |
|
|
2019
Q3 | $6.7M | Buy |
164,758
+10,679
| +7% | +$452K | 0.02% | 590 |
|
|
2019
Q2 | $6.62M | Buy |
154,079
+2,928
| +2% | +$113K | 0.03% | 580 |
|
|
2019
Q1 | $5.8M | Sell |
151,151
-28,764
| -16% | -$1.1M | 0.02% | 593 |
|
|
2018
Q4 | $6.36M | Buy |
179,915
+77,128
| +75% | +$2.8M | 0.03% | 459 |
|
|
2018
Q3 | $3.96M | Buy |
102,787
+21,116
| +26% | +$738K | 0.02% | 741 |
|
|
2018
Q2 | $2.67M | Buy |
81,671
+1,415
| +2% | +$42.7K | 0.01% | 874 |
|
|
2018
Q1 | $2.19M | Buy |
80,256
+28,680
| +56% | +$779K | 0.01% | 890 |
|
|
2017
Q4 | $1.28M | Sell |
51,576
-28,864
| -36% | -$796K | 0.01% | 1152 |
|
|
2017
Q3 | $2.35M | Buy |
80,440
+35,944
| +81% | +$993K | 0.02% | 850 |
|
|
2017
Q2 | $1.23M | Buy |
44,496
+1,178
| +3% | +$31.3K | 0.01% | 1132 |
|
|
2017
Q1 | $1.08M | Buy |
43,318
+4,657
| +12% | +$113K | 0.01% | 1135 |
|
|
2016
Q4 | $836K | Sell |
38,661
-10,049
| -21% | -$219K | 0.01% | 1218 |
|
|
2016
Q3 | $1.16M | Buy |
48,710
+8,648
| +22% | +$206K | 0.01% | 1019 |
|
|
2016
Q2 | $936K | Buy |
40,062
+5,187
| +15% | +$112K | 0.01% | 1078 |
|
|
2016
Q1 | $656K | Buy |
34,875
+6,892
| +25% | +$121K | 0.01% | 1133 |
|
|
2015
Q4 | $516K | Buy |
+27,983
| New | +$501K | 0.01% | 1187 |
|
Other funds holding BSX
Raymond James Financial Services Advisors's BSX Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its Boston Scientific (BSX) stake by 10% in Q3 2024, buying an estimated $4.97M and bringing the position to 674,764 shares worth $56.5M. The position accounts for 0.08% of the portfolio, ranked #245.
Raymond James Financial Services Advisors first reported a position in BSX in Q4 2015 and has held it in 36 quarters since. 1,396 funds tracked by Wall St. Rank hold BSX as of Q3 2024.
- Raymond James Financial Services Advisors held 674,764 shares of Boston Scientific worth $56.5M as of Q3 2024.
- Raymond James Financial Services Advisors bought 63,071 Boston Scientific shares in Q3 2024, an estimated $4.97M.
- Boston Scientific made up 0.08% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #245 holding.
- Raymond James Financial Services Advisors first reported a position in Boston Scientific in Q4 2015 and has held it in 36 quarters since.
- 1,396 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.